Benzinga (Tue, 23-Apr 3:05 PM ET)
Novartis wins pediatric indication for Lutathera for rare cancer
Seeking Alpha News (Tue, 23-Apr 2:08 PM ET)
Sanofi reportedly lining up banks for consumer products spinoff
Seeking Alpha News (Tue, 23-Apr 1:32 PM ET)
Biggest stock movers today: SPOT, GM, DHR, IBRX, NVS, and more
Seeking Alpha News (Tue, 23-Apr 9:36 AM ET)
Biggest stock movers today: DHR, IBRX, NVS, and more
Seeking Alpha News (Tue, 23-Apr 8:36 AM ET)
Biggest stock movers today: GM, DHR, IBRX, NVS, and more
Seeking Alpha News (Tue, 23-Apr 8:36 AM ET)
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Benzinga (Tue, 23-Apr 8:25 AM ET)
Novartis Q1 Results Surge, 2024 Outlook Brightens
TipRanks (Tue, 23-Apr 6:59 AM ET)
Benzinga (Tue, 23-Apr 6:55 AM ET)
NVS Earnings: Novartis Beats Q1 Estimates, Raises Outlook
TipRanks (Tue, 23-Apr 6:15 AM ET)
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Novartis Ag trades on the NYSE stock market under the symbol NVS.
As of April 25, 2024, NVS stock price declined to $98.32 with 413,504 million shares trading.
NVS has a beta of 0.36, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.06 to the broad based SPY ETF.
NVS has a market cap of $200.61 billion. This is considered a Mega Cap stock.
Last quarter Novartis Ag reported $12 billion in Revenue and $1.80 earnings per share. This beat revenue expectation by $349 million and exceeded earnings estimates by $.11.
In the last 3 years, NVS stock traded as high as $108.78 and as low as $74.09.
The top ETF exchange traded funds that NVS belongs to (by Net Assets): DFIV, FVD, DFAI, GCOW, AVDE.
NVS has underperformed the market in the last year with a return of +1.5%, while the SPY ETF gained +22.6%. In the last 3 month period, NVS fell short of the market, returning -5.1%, while SPY returned +3.2%. However, in the most recent 2 weeks NVS has outperformed the stock market by returning +4.2%, while SPY returned -2.9%.
NVS support price is $97.26 and resistance is $99.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS stock will trade within this expected range on the day.